Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 Next >
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers MRNA TAK
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers SGEN TAK
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Completion of Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From TAKEDA PHARMACEUTICAL COMPANY LIMITED
Via Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.